- Home
- DXYZ vs PGEN Comparison
DXYZ vs PGEN Comparison
Compare DXYZ & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DXYZ | PGEN |
|---|---|---|
| Founded | N/A | 1998 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | DXYZ | PGEN |
|---|---|---|
| Price | $25.67 | $5.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 3.3M | ★ 5.8M |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | N/A | $81.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.71 | $1.47 |
| 52 Week High | $72.87 | $6.04 |
Technical Indicators
Market Signals| Indicator | DXYZ | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 39.06 | 62.17 |
| Support Level | $24.03 | $3.32 |
| Resistance Level | $29.69 | $6.04 |
| Average True Range (ATR) | 1.55 | 0.35 |
| MACD | 0.41 | -0.01 |
| Stochastic Oscillator | 38.32 | 67.93 |
Price Performance
Historical ComparisonAbout DXYZ Destiny Tech100 Inc.
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It is designed to be an investment portfolio of the Top 100 High-Growth Tech Companies.
About PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.